Underestimating cardiac toxicity in cancer trials: Lessons learned?

Journal of Clinical Oncology

Volumn 30, Issue 16, 2012, Pages 1916-1918

  Witteles, Ronald M ^a   Telli, Melinda ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB;

CANCER PATIENT; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DRUG WITHDRAWAL; GASTROINTESTINAL STROMAL TUMOR; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; KIDNEY CARCINOMA; NOTE; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIDE EFFECT;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS AS TOPIC; DRUG LABELING; DRUG MONITORING; HEART DISEASES; HUMANS; INDOLES; NEOPLASMS; PYRROLES; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84863957259     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.4012     Document Type: Note

References (13)

1. Sutent prescribing information. http://labeling.pfizer.com/ShowLabeling. aspx?id=607. Accessed October 5, 2011
2. Richards CJ, Je Y, Schutz FA, et al: Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 29:3450-3456, 2011
3. Fiedler W, Serve H, Dohner H, et al: A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105:986-993, 2005 (Pubitemid 40170865)
4. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and plateletderived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24, 2006 (Pubitemid 46630489)
5. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006 (Pubitemid 44528723)
6. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
7. Sutent prescribing information. http://www.pfizer.com/files/products/ uspi-sutent.pdf. Accessed November 1, 2008
8. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
9. US Department of Health and Human Services: Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE- 4.03-2010-06-14-QuickReference-8.5x11.pdf
10. Jessup M, Abraham WT, Casey DE, et al: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. Circulation 119:1977-2016, 2009
11. Chu TF, Rupnick MA, Kerkela R, et al: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011-2019, 2007 (Pubitemid 350236338)
12. Telli ML, Witteles RM, Fisher GA, et al: Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 19:1613-1618, 2008
13. Cheng H, Force T: Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 106:21-34, 2010